Taysha Gene Therapies, Inc. (TSHA) Free cash flow
- Free cash flow · 12 months (USD): Value $-132.57M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -2416.99%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-132.57M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-132.19M − $381.00K ≈ $-132.57M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -2416.99% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-132.57M ÷ $5.49M × 100 ≈ -2416.99% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-132.19M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.88× | Operating cash flow / net income. Period ending 2026-06-30. $-132.19M ÷ $-149.63M ≈ 0.88× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -132.19M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 381.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -132.57M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 5.49M USD | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -149.63M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-132.57M | (m) | $-132.19M | $381.00K | (m) | $5.49M | (m) | $-149.63M | (m) | (m) | -2416.99% | 0.88× |
| 2026-03-31 | $-112.33M | (m) | $-111.95M | $384.00K | (m) | $7.47M | (m) | $-129.88M | (m) | (m) | -1503.57% | 0.86× |
| 2025-12-31 | $-93.83M | (m) | $-93.09M | $738.00K | (m) | $9.77M | (m) | $-109.00M | (m) | (m) | -960.07% | 0.85× |
| 2025-09-30 | $-85.16M | (m) | $-84.68M | $486.00K | (m) | $6.31M | (m) | $-99.93M | (m) | (m) | -1349.64% | 0.85× |
| 2025-06-30 | $-82.54M | (m) | $-82.13M | $413.00K | (m) | $8.10M | (m) | $-92.72M | (m) | (m) | -1019.24% | 0.89× |
| 2025-03-31 | (m) | (m) | $-83.45M | (m) | (m) | $7.22M | (m) | $-86.77M | (m) | (m) | (m) | 0.96× |
| 2024-12-31 | $-81.60M | (m) | $-81.22M | $374.00K | (m) | $8.33M | (m) | $-89.30M | (m) | (m) | -979.23% | 0.91× |
| 2024-09-30 | $-79.43M | (m) | $-79.03M | $393.00K | (m) | $9.91M | (m) | $-22.77M | (m) | (m) | -801.08% | 3.47× |
| 2024-06-30 | $-75.73M | (m) | $-75.37M | $358.00K | (m) | $12.87M | (m) | $-114.33M | (m) | (m) | -588.25% | 0.66× |
| 2024-03-31 | $-72.74M | (m) | $-72.63M | $109.00K | (m) | $14.16M | (m) | $-118.00M | (m) | (m) | -513.85% | 0.62× |
| 2023-12-31 | $-76.89M | (m) | $-73.02M | $3.87M | (m) | $15.45M | (m) | $-111.57M | (m) | (m) | -497.62% | 0.65× |
| 2023-09-30 | $-48.35M | (m) | $-42.19M | $6.16M | (m) | (m) | (m) | $-214.38M | (m) | (m) | (m) | 0.20× |
| 2023-06-30 | $-61.23M | (m) | $-53.05M | $8.18M | (m) | (m) | (m) | $-123.83M | (m) | (m) | (m) | 0.43× |
| 2023-03-31 | $-83.73M | (m) | $-67.64M | $16.09M | (m) | (m) | (m) | $-133.32M | (m) | (m) | (m) | 0.51× |
| 2022-12-31 | $-109.01M | (m) | $-88.39M | $20.62M | (m) | $2.50M | (m) | $-166.01M | (m) | (m) | -4356.87% | 0.53× |
| 2022-09-30 | $-169.50M | (m) | $-142.93M | $26.58M | (m) | (m) | (m) | $-160.68M | (m) | (m) | (m) | 0.89× |
| 2022-06-30 | $-174.26M | (m) | $-146.20M | $28.06M | (m) | (m) | (m) | $-185.56M | (m) | (m) | (m) | 0.79× |
| 2022-03-31 | $-159.01M | (m) | $-135.81M | $23.20M | (m) | (m) | (m) | $-192.61M | (m) | (m) | (m) | 0.71× |
| 2021-12-31 | $-132.35M | (m) | $-117.04M | $15.30M | (m) | (m) | (m) | $-174.52M | (m) | (m) | (m) | 0.67× |
| 2021-09-30 | $-103.72M | (m) | $-96.63M | $7.08M | (m) | (m) | (m) | $-142.46M | (m) | (m) | (m) | 0.68× |
| 2021-06-30 | (m) | (m) | $-71.42M | (m) | (m) | (m) | (m) | $-106.31M | (m) | (m) | (m) | 0.67× |
| 2021-03-31 | $-51.68M | (m) | $-51.06M | $616.00K | (m) | (m) | (m) | $-86.60M | (m) | (m) | (m) | 0.59× |
| 2020-12-31 | $-30.81M | (m) | $-30.73M | $82.00K | (m) | (m) | (m) | $-60.01M | (m) | (m) | (m) | 0.51× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |